BG63992B1 - Амидно съединение и приложение му като rho киназен инхибитор - Google Patents

Амидно съединение и приложение му като rho киназен инхибитор Download PDF

Info

Publication number
BG63992B1
BG63992B1 BG107195/2002A BG10719502A BG63992B1 BG 63992 B1 BG63992 B1 BG 63992B1 BG 107195/2002 A BG107195/2002 A BG 107195/2002A BG 10719502 A BG10719502 A BG 10719502A BG 63992 B1 BG63992 B1 BG 63992B1
Authority
BG
Bulgaria
Prior art keywords
pharmaceutically acceptable
isomer
kinase inhibitor
hydrogen
salt
Prior art date
Application number
BG107195/2002A
Other languages
Bulgarian (bg)
English (en)
Inventor
Masayoshi Uehata
Takashi Ono
Hiroyuki Satoh
Keiji Yamagami
Toshio Kawahara
Original Assignee
Welfide Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16622116&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG63992(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Welfide Corporation filed Critical Welfide Corporation
Publication of BG63992B1 publication Critical patent/BG63992B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials Applied To Surfaces To Minimize Adherence Of Mist Or Water (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Enzymes And Modification Thereof (AREA)
BG107195/2002A 1996-08-12 1999-03-12 Амидно съединение и приложение му като rho киназен инхибитор BG63992B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21240996 1996-08-12
PCT/JP1997/002793 WO1998006433A1 (en) 1996-08-12 1997-08-08 MEDICINES COMPRISING Rho KINASE INHIBITOR

Publications (1)

Publication Number Publication Date
BG63992B1 true BG63992B1 (bg) 2003-09-30

Family

ID=16622116

Family Applications (4)

Application Number Title Priority Date Filing Date
BG107195/2002A BG107195A (en) 1996-08-12 1999-03-12 AMIDE COMPOUND AND ITS APPLICATION AS Rho KINASE INHIBITOR
BG107195/2002A BG63992B1 (bg) 1996-08-12 1999-03-12 Амидно съединение и приложение му като rho киназен инхибитор
BG103246A BG63991B1 (bg) 1996-08-12 1999-03-12 Фармацевтично средство, съдържащо rно киназен инхибитор
BG107645/2003A BG107645A (en) 1996-08-12 2003-03-19 MEDICINES COMPRISING Rho KINASE INHIBITOR

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BG107195/2002A BG107195A (en) 1996-08-12 1999-03-12 AMIDE COMPOUND AND ITS APPLICATION AS Rho KINASE INHIBITOR

Family Applications After (2)

Application Number Title Priority Date Filing Date
BG103246A BG63991B1 (bg) 1996-08-12 1999-03-12 Фармацевтично средство, съдържащо rно киназен инхибитор
BG107645/2003A BG107645A (en) 1996-08-12 2003-03-19 MEDICINES COMPRISING Rho KINASE INHIBITOR

Country Status (25)

Country Link
US (3) US6218410B1 (cs)
EP (1) EP0956865B2 (cs)
JP (1) JP3669711B2 (cs)
KR (2) KR100595740B1 (cs)
CN (1) CN100389828C (cs)
AT (1) ATE359822T1 (cs)
AU (1) AU738620B2 (cs)
BG (4) BG107195A (cs)
BR (1) BR9711154A (cs)
CA (1) CA2263425C (cs)
CZ (1) CZ301044B6 (cs)
DE (1) DE69737631T3 (cs)
DK (1) DK0956865T4 (cs)
EE (1) EE9900050A (cs)
ES (1) ES2286834T5 (cs)
HU (1) HU229864B1 (cs)
IL (1) IL128456A0 (cs)
IS (1) IS4973A (cs)
NO (1) NO990622L (cs)
NZ (2) NZ513800A (cs)
PL (1) PL331561A1 (cs)
PT (1) PT956865E (cs)
RU (3) RU2206321C2 (cs)
SI (1) SI0956865T2 (cs)
WO (1) WO1998006433A1 (cs)

Families Citing this family (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513800A (en) 1996-08-12 2001-09-28 Welfide Corp Treatment of diseases using Rho kinase inhibitors
US20080233098A1 (en) * 1997-10-31 2008-09-25 Mckerracher Lisa RHO Family Antagonists and Their Use to Block Inhibition of Neurite Outgrowth
CA2327276A1 (en) * 1998-04-23 1999-10-28 Hiroshi Muramatsu Isoquinolinesulfonamide derivatives and drugs containing the same as the active ingredient
AU5198199A (en) * 1998-08-17 2000-03-06 Senju Pharmaceutical Co., Ltd. Preventives/remedies for glaucoma
US7169783B2 (en) * 1998-11-02 2007-01-30 Universite De Montreal (+)-Trans-4-(1-aminoethyl)-1-(4-pyridycarbamoyl)-cyclohexane and method for promoting neural growth in the central nervous system and in a patient at a site of neuronal lesion
ES2295009T3 (es) 1999-03-25 2008-04-16 Mitsubishi Tanabe Pharma Corporation Inhibidores de rho quinasa para la profilaxis y el tratamiento de neumonia intersticial y fibrosis pulmonar.
WO2000057914A1 (en) * 1999-03-25 2000-10-05 Santen Pharmaceutical Co., Ltd. Ocular tension-lowering agents
AU3987800A (en) * 1999-04-22 2000-11-10 Mitsubishi Pharma Corporation Preventives/remedies for angiostenosis
EP1177796B1 (en) 1999-04-27 2011-04-27 Mitsubishi Tanabe Pharma Corporation Medicament for prevention or therapeutic treatment of liver disease
AU5250400A (en) * 1999-06-18 2001-01-09 Mitsubishi Pharma Corporation Osteogenesis promoters
JP2001081031A (ja) * 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
WO2001017562A1 (fr) * 1999-09-02 2001-03-15 Yamanouchi Pharmaceutical Co., Ltd. Agents promoteurs de l'osteogenese
AU7451200A (en) * 1999-09-29 2001-04-30 Mitsubishi Pharma Corporation Analgesics
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
JP4776136B2 (ja) * 2000-03-16 2011-09-21 田辺三菱製薬株式会社 アミド化合物およびその用途
AU2001236006A1 (en) * 2000-03-31 2001-10-15 Mitsubishi Pharma Corporation Preventives/remedies for kidney diseases
ES2344831T3 (es) * 2000-06-23 2010-09-08 Mitsubishi Tanabe Pharma Corporation Potenciadores de un efecto antitumoral.
HUP0302429A3 (en) * 2000-09-20 2004-01-28 Merck Patent Gmbh 4-amino-quinazolines, process for producing them, pharmaceutical compositions containing them and their use
WO2002024667A1 (en) * 2000-09-20 2002-03-28 Merck Patent Gmbh 4-amino-quinazolines
JP4582561B2 (ja) * 2000-10-23 2010-11-17 旭化成ファーマ株式会社 移植による血管病変の発生抑制剤
JP2002139493A (ja) * 2000-11-01 2002-05-17 Sumitomo Pharmaceut Co Ltd 新規なハイスループット・スクリーニング方法
CA2325842C (en) * 2000-11-02 2007-08-07 Lisa Mckerracher Methods for making and delivering rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof
US20020177207A1 (en) * 2001-03-14 2002-11-28 Myriad Genetics, Incorporated Tsg101-interacting proteins and use thereof
US20020132832A1 (en) * 2001-01-05 2002-09-19 Mills Thomas M. Treatment of erectile dysfunction
JP2002226375A (ja) * 2001-01-31 2002-08-14 Asahi Kasei Corp 線維化予防、治療剤
WO2002098370A2 (en) * 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
MXPA03008659A (es) * 2001-03-23 2005-04-08 Bayer Ag Inhibidores de rho-cinasa.
US20030125344A1 (en) * 2001-03-23 2003-07-03 Bayer Corporation Rho-kinase inhibitors
CN100411686C (zh) * 2001-04-11 2008-08-20 千寿制药株式会社 视觉功能障碍改善剂
US7442686B2 (en) 2001-04-12 2008-10-28 Bioaxone Therapeutique Inc. Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
JPWO2002100833A1 (ja) * 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
JP5042419B2 (ja) * 2001-08-15 2012-10-03 旭化成ファーマ株式会社 骨形成促進剤および骨形成促進組成物
US7829566B2 (en) * 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
DE10153605A1 (de) * 2001-11-02 2003-05-28 Morphochem Ag Komb Chemie Verwendung von Inhibitoren der Rho-Kinasen zur Stimulation des Nervenwachstums, zur Inhibition der Narbengewebsbildung und/oder Reduktion eines Sekundärschadens
WO2003047591A1 (fr) * 2001-11-30 2003-06-12 Asahi Kasei Pharma Corporation Medicaments contre l'hypertension arterielle pulmonaire primitive
FR2833840B1 (fr) * 2001-12-21 2010-06-18 Rytek Methodes et compositions pour le traitement de pathologies respiratoires
DE60320933D1 (de) * 2002-01-10 2008-06-26 Bayer Healthcare Ag Rho-kinase inhibitoren
MXPA04007196A (es) * 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
JP4469179B2 (ja) * 2002-01-23 2010-05-26 バイエル ファーマセチカル コーポレーション Ｒｈｏキナーゼ阻害剤としてのピリミジン誘導体
GB0206860D0 (en) * 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
US7645878B2 (en) * 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
EP1500643A4 (en) * 2002-04-03 2007-03-28 Dainippon Sumitomo Pharma Co benzamidine
US20040028716A1 (en) * 2002-06-14 2004-02-12 Marks Andrew R. Use of Y-27632 as an agent to prevent restenosis after coronary artery angioplasty/stent implantation
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
CN1681525A (zh) * 2002-07-12 2005-10-12 曹义海 一种抑制血管渗漏和组织水肿的方法
US7094789B2 (en) 2002-07-22 2006-08-22 Asahi Kasei Pharma Corporation 5-substituted isoquinoline derivatives
AU2003281623B8 (en) * 2002-07-22 2009-06-11 Asahi Kasei Pharma Corporation 5-substituted isoquinoline derivative
DE10233737A1 (de) * 2002-07-24 2004-02-05 Morphochem Aktiengesellschaft für kombinatorische Chemie Verwendung von Modulatoren des Signaltransduktionswegs über die Proteinkinase Fyn zur Behandlung von Tumorerkrankungen
AU2003257960A1 (en) * 2002-08-01 2004-03-03 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Cell modulation using a cytoskeletal protein
ATE546143T1 (de) * 2002-08-29 2012-03-15 Santen Pharmaceutical Co Ltd Mittel zur behandlung von glaukom mit einem rho- kinase-hemmer und prostaglandinen
CA2400996A1 (en) * 2002-09-03 2004-03-03 Lisa Mckerracher 1,4-substituted cyclohexane derivatives
EP1550660A1 (en) * 2002-09-12 2005-07-06 Kirin Beer Kabushiki Kaisha Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same
US20050215601A1 (en) * 2002-09-25 2005-09-29 Santen Pharmaceutical Co., Ltd. Therapeutic agent for rheumatic disease comprising benzamide derivative as active ingredient
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7972612B2 (en) 2002-11-18 2011-07-05 Santen Pharmaceutical Co., Ltd. Remedy for glaucoma comprising Rho kinase inhibitor and β-blocker
AU2003901270A0 (en) * 2003-03-18 2003-04-03 Medvet Science Pty. Ltd. A method of modulating muscle cell functioning
AU2004221792C1 (en) * 2003-03-18 2009-09-24 Medvet Science Pty. Ltd. A method of modulating smooth muscle cell functioning by modulating sphingosine kinase mediated signalling
GB2400316A (en) * 2003-04-10 2004-10-13 Richard Markoll Electromagnetic stimulation in patients with osteoporosis
JP4764818B2 (ja) 2003-04-11 2011-09-07 メディミューン，エルエルシー 組換えｉｌ−９抗体およびその使用
KR101076638B1 (ko) 2003-04-18 2011-10-27 센주 세이야꾸 가부시키가이샤 각막 지각 회복제
WO2004105757A2 (en) * 2003-05-29 2004-12-09 Schering Aktiengesellschaft Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
US20110098232A1 (en) * 2003-05-30 2011-04-28 Zeilig Charles E Methods For The Selective Treatment Of Tumors By Calcium-Mediated Induction Of Apoptosis
WO2004108142A2 (en) * 2003-06-06 2004-12-16 The University Of Manchester Inhibitors of tip-1 for treatment tissue damage
US7160894B2 (en) 2003-06-06 2007-01-09 Asahi Kasei Pharma Corporation Tricyclic compound
WO2005017160A2 (en) * 2003-08-13 2005-02-24 Children's Hospital Medical Center Mobilization of hematopoietic cells
JP2007535479A (ja) 2003-08-13 2007-12-06 チルドレンズ ホスピタル メディカル センター ＧＴＰａｓｅを調節するためのキメラペプチド
EP1660186B1 (en) 2003-08-18 2013-12-25 MedImmune, LLC Humanization of antibodies
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
US7371850B1 (en) 2003-08-20 2008-05-13 Myriad Genetics, Inc. Method and composition for reducing expression of ROCK-II
EP2468729B1 (en) 2003-10-15 2013-12-25 Ube Industries, Ltd. Novel indazole derivative
US20050238666A1 (en) * 2003-12-05 2005-10-27 Williams David A Methods of enhancing stem cell engraftment
CA2550361C (en) 2003-12-19 2014-04-29 Prabha Ibrahim Compounds and methods for development of ret modulators
TW200526224A (en) * 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
PL1696958T3 (pl) * 2003-12-22 2007-08-31 Alcon Inc Środki do leczenia retinopatii jaskrowej i neuropatii wzrokowej
EP1696926A1 (en) * 2003-12-22 2006-09-06 Alcon, Inc. Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration
WO2005080394A1 (en) * 2004-02-24 2005-09-01 Bioaxone Therapeutique Inc. 4-substituted piperidine derivatives
WO2005094824A1 (en) * 2004-03-25 2005-10-13 East Carolina University Methods of enhancing cancer therapy by protecting nerve cells
US20060115870A1 (en) * 2004-03-30 2006-06-01 Alcon, Inc. High throughput assay for human Rho kinase activity
WO2005102345A1 (en) * 2004-03-30 2005-11-03 Alcon, Inc. Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
US20080096238A1 (en) * 2004-03-30 2008-04-24 Alcon, Inc. High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio
ES2671522T3 (es) 2004-04-02 2018-06-06 The Regents Of The University Of California Métodos y composiciones para tratar y prevenir una enfermedad asociada con la integrina alfa V beta 5
WO2005118582A1 (ja) * 2004-06-03 2005-12-15 Senju Pharmaceutical Co., Ltd. アミド化合物を含有する角膜知覚回復剤
US20060121042A1 (en) 2004-10-27 2006-06-08 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
FR2879100B1 (fr) 2004-12-09 2007-07-06 Lionel Bueno Compositions pour le traitement des pathologies oculaires de surface et de la retine
AR054416A1 (es) * 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
WO2006071548A2 (en) * 2004-12-27 2006-07-06 Alcon, Inc. Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
WO2006088088A1 (ja) * 2005-02-16 2006-08-24 Astellas Pharma Inc. Ｒｏｃｋ阻害剤を含有する疼痛治療剤
JP5153613B2 (ja) 2005-03-18 2013-02-27 メディミューン，エルエルシー 抗体のフレームワーク・シャッフル
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
EP1893647A2 (en) 2005-06-23 2008-03-05 MedImmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
NZ565040A (en) 2005-06-28 2010-05-28 Sanofi Aventis Isoquinoline derivatives as inhibitors of RHO-kinase
KR101373535B1 (ko) 2005-07-26 2014-03-12 사노피 Ｒｈｏ-키나제 억제제로서의 피페리디닐-치환된 이소퀴놀론유도체
JP5049970B2 (ja) 2005-07-26 2012-10-17 サノフイ Ｒｈｏ−キナーゼ阻害剤としてのシクロヘキシルアミンイソキノロン誘導体
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
KR101149954B1 (ko) 2005-08-30 2012-06-01 아사히 가세이 파마 가부시키가이샤 술폰아미드 화합물
US8211919B2 (en) 2005-09-02 2012-07-03 Astellas Pharma Inc. Amide derivatives as rock inhibitors
JP4832051B2 (ja) * 2005-10-21 2011-12-07 学校法人順天堂 半月体形成性腎病変治療剤
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP1951253A2 (en) * 2005-10-26 2008-08-06 Cotherix, Inc. Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US7867999B1 (en) 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
EP1962853A1 (en) * 2005-12-22 2008-09-03 Alcon Research, Ltd. (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007142323A1 (ja) 2006-06-08 2007-12-13 Ube Industries, Ltd. 側鎖にスピロ環構造を有する新規インダゾール誘導体
BRPI0714782A2 (pt) * 2006-07-31 2013-07-16 Senju Pharma Co preparaÇço lÍquida aquosa contendo composto de amida
WO2008022182A1 (en) * 2006-08-16 2008-02-21 The Uab Research Foundation Methods for promoting coupling between bone formation and resorption
ES2439994T3 (es) 2006-08-28 2014-01-27 Kyowa Hakko Kirin Co., Ltd. Anticuerpos antagonistas monoclonales humanos específicos de LIGHT humano
GB0617222D0 (en) * 2006-08-31 2006-10-11 Vereniging Het Nl Kanker I Antibiotics
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20090036465A1 (en) * 2006-10-18 2009-02-05 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
RU2439057C2 (ru) * 2006-11-28 2012-01-10 Эмкьюар Фармасьютикалз Лимитед Способ получения противорвотного препарата
WO2008079945A2 (en) * 2006-12-20 2008-07-03 University Of South Florida Rock inhibitors and uses thereof
AR064420A1 (es) * 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
NZ577980A (en) 2006-12-27 2012-01-12 Sanofi Aventis Cycloalkylamine substituted isoquinolone derivatives
WO2008077555A2 (en) 2006-12-27 2008-07-03 Sanofi-Aventis Substituted isoquinolines and their use as rho-kinase inhibitors
EP2114920A1 (en) 2006-12-27 2009-11-11 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives
RU2455302C2 (ru) 2006-12-27 2012-07-10 Санофи-Авентис ЗАМЕЩЕННЫЕ ИЗОХИНОЛИНОВЫЕ И ИЗОХИНОЛИНОНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
KR20090092303A (ko) 2006-12-27 2009-08-31 사노피-아벤티스 사이클로알킬아민 치환된 이소퀴놀린 유도체
RU2468011C2 (ru) 2006-12-27 2012-11-27 Санофи-Авентис Замещенные циклоалкиламином производные изохинолина и изохинолинона
WO2008089351A1 (en) * 2007-01-17 2008-07-24 Wisconsin Alumni Research Foundation Improved culture of stem cells
US8415372B2 (en) 2007-02-27 2013-04-09 Asahi Kasei Pharma Corporation Sulfonamide compound
US7964613B2 (en) 2007-02-28 2011-06-21 Asahi Kasei Pharma Corporation Sulfonamide compound
KR101566171B1 (ko) 2007-03-09 2015-11-06 삼성전자 주식회사 디지털 저작권 관리 방법 및 장치
CA2682292A1 (en) 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
EP2155769B1 (en) 2007-05-04 2012-06-27 Katholieke Universiteit Leuven KU Leuven Research & Development Tissue degeneration protection
CA2690753C (en) 2007-07-02 2013-08-13 Asahi Kasei Pharma Corporation Sulfonamide compound and crystal thereof
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
KR20210070407A (ko) * 2007-08-29 2021-06-14 센주 세이야꾸 가부시키가이샤 각막 내피 세포 접착 촉진제
WO2009140200A1 (en) * 2008-05-12 2009-11-19 Amnestix, Inc. Compounds for improving learning and memory
CN102131784B (zh) 2008-06-24 2014-08-27 赛诺菲-安万特 作为rho激酶抑制剂的取代的异喹啉和异喹啉酮
PT2313374E (pt) 2008-06-24 2013-11-29 Sanofi Sa Isoquinolinas e isoquinolinonas 6-substituídas
HRP20131040T1 (hr) 2008-06-24 2013-12-06 Sanofi Bi- i policikliäśki supstituirani izokinolin i derivati izokinolina kao inhibitori rho-kinaze
US20110130388A1 (en) 2008-07-24 2011-06-02 Yasushi Ikuno Prophylactic or therapeutic agent for axial myopia
MX2011002825A (es) * 2008-09-18 2011-04-05 Astellas Pharma Inc Compuestos heterociclicos de carboxamida.
EP2177218A1 (en) 2008-10-15 2010-04-21 Medizinische Universität Wien Regenerative therapy
EP2177510A1 (en) 2008-10-17 2010-04-21 Universität des Saarlandes Allosteric protein kinase modulators
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
KR101739994B1 (ko) 2009-04-03 2017-05-25 에프. 호프만-라 로슈 아게 프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
WO2011021221A2 (en) 2009-08-17 2011-02-24 Reliance Life Sciences Pvt. Ltd. Compositions for spinal cord injury
AU2010306627B2 (en) 2009-10-16 2014-07-17 The Scripps Research Institute Induction of pluripotent cells
NZ599866A (en) 2009-11-06 2014-09-26 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
CN102188697B (zh) * 2010-03-03 2014-11-05 中国医学科学院药物研究所 重组人Rho激酶在制备药物中的应用
CA2797033C (en) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
WO2012087965A2 (en) 2010-12-22 2012-06-28 Fate Therapauetics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
KR101911972B1 (ko) 2011-02-07 2018-10-25 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
EP2628482A1 (en) 2012-02-17 2013-08-21 Academisch Medisch Centrum Rho kinase inhiitors for use in the treatment of neuroblastoma
US9273006B2 (en) * 2012-05-08 2016-03-01 Syddansk Universitet Anabolic compounds for treating and preventing bone loss diseases
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
CN116574185A (zh) 2012-07-25 2023-08-11 塞尔德克斯医疗公司 抗kit抗体及其用途
WO2014059028A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
US9789164B2 (en) 2013-03-15 2017-10-17 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
US20160339018A1 (en) 2013-04-24 2016-11-24 Kyushu University, National University Corporation Therapeutic agent for ocular fundus disease
WO2014177699A1 (en) * 2013-05-03 2014-11-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Rhoa (rock) inhibitors for the treatment of enflammatory bowel disease
SG11201509982UA (cs) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
KR102313341B1 (ko) 2013-08-26 2021-10-18 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
SG11201606934SA (en) 2014-03-04 2016-09-29 Fate Therapeutics Inc Improved reprogramming methods and cell culture platforms
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
DK3154583T3 (da) 2014-06-04 2021-03-22 Biontech Res And Development Inc Humane monoklonale antistoffer mod gangliosid gd2
CA2953524A1 (en) 2014-06-27 2015-12-30 The Regents Of The University Of California Cultured mammalian limbal stem cells, methods for generating the same, and uses thereof
PL3333191T3 (pl) 2014-12-11 2021-05-04 Pierre Fabre Médicament Przeciwciała przeciwko c10orf54 i ich zastosowania
US10106525B2 (en) 2015-01-26 2018-10-23 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10149856B2 (en) 2015-01-26 2018-12-11 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US10857157B2 (en) 2015-01-26 2020-12-08 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
CA2976074A1 (en) 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
MX2017011194A (es) 2015-03-03 2018-04-10 Kymab Ltd Anticuerpos, usos y métodos.
EP3313449B1 (en) 2015-06-24 2020-09-23 Nitto Denko Corporation Ionizable compounds and compositions and uses thereof
WO2017064119A1 (en) 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
EP4088719A1 (en) 2015-10-13 2022-11-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
SG10202111851YA (en) 2015-10-16 2021-12-30 Fate Therapeutics Inc Platform for the Induction & Maintenance of Ground State Pluripotency
KR102815803B1 (ko) 2015-12-02 2025-06-05 주식회사 에스티사이언스 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
CN114470194A (zh) 2015-12-02 2022-05-13 斯特库伯株式会社 与btn1a1免疫特异性结合的抗体和分子及其治疗用途
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US11198680B2 (en) 2016-12-21 2021-12-14 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US12215151B2 (en) 2017-05-31 2025-02-04 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
KR20200015602A (ko) 2017-05-31 2020-02-12 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
CN110997724A (zh) 2017-06-06 2020-04-10 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
US10537567B2 (en) 2017-07-11 2020-01-21 BioAxone BioSciences, Inc. Kinase inhibitors for treatment of disease
US11707522B2 (en) 2017-10-13 2023-07-25 Boehringer Ingelheim International Gmbh Human antibodies to Tn antigen
CA3086457A1 (en) 2017-12-21 2019-06-27 Santen Pharmaceutical Co., Ltd. Medicament comprising combination of sepetaprost and rho-associated coiled-coil containing protein kinase inhibitor
KR102767692B1 (ko) 2018-07-20 2025-02-17 피에르 파브르 메디카먼트 Vista의 수용체
EP3843845B1 (en) 2018-08-29 2026-03-11 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
UY38427A (es) 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares
CN111116555B (zh) * 2018-10-30 2023-06-02 北京盈科瑞创新药物研究有限公司 一种Rho激酶抑制剂及其制备方法和应用
WO2020193802A1 (en) 2019-03-28 2020-10-01 Fundación De La Comunidad Valenciana Centro De Investigación Príncipe Felipe Polymeric conjugates and uses thereof
WO2021138331A2 (en) * 2019-12-30 2021-07-08 Memorial Sloan Kettering Cancer Center Small molecule inhibitors of ulk1
CN115667504A (zh) 2020-04-27 2023-01-31 诺华股份有限公司 用于眼细胞疗法的方法和组合物
CN111707831A (zh) * 2020-07-16 2020-09-25 首都医科大学附属北京朝阳医院 Rock激酶活性在辅助诊断sle以及评价sle病情中的应用
EP4274578A1 (en) 2021-01-11 2023-11-15 Incyte Corporation Combination therapy comprising jak pathway inhibitor and rock inhibitor
CN113262226B (zh) * 2021-04-19 2023-05-16 杭州市第一人民医院 利舒地尔在制备细菌感染治疗药物中的应用
CN118159645A (zh) 2021-10-18 2024-06-07 埃维亚生命科学有限公司 组合物及使用其治疗肝纤维化的方法
KR20240093785A (ko) 2021-10-22 2024-06-24 에비아 라이프 사이언시스 인코포레이션 세포외 소포의 제조 방법, 이의 조성물 및 사용 방법
US20250382359A1 (en) 2021-12-22 2025-12-18 Byomass Inc. Targeting gdf15-gfral pathway
WO2023147107A1 (en) 2022-01-31 2023-08-03 Byomass Inc. Myeloproliferative conditions
WO2025224050A1 (en) 2024-04-22 2025-10-30 Institut National de la Santé et de la Recherche Médicale Methods of treatment of patients suffering from hypomelanosis of ito

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0227992B2 (ja) 1982-01-14 1990-06-20 Asahi Kasei Kogyo Kk Isokinorinsuruhonirukagobutsu
JPS58121278A (ja) 1982-01-12 1983-07-19 Asahi Chem Ind Co Ltd イソキノリンスルホン酸アミド誘導体
US4456757A (en) † 1981-03-20 1984-06-26 Asahi Kasei Kogyo Kabushiki Kaisha Isoquinolinesulfonyl derivatives and process for the preparation thereof
JPS57200366A (en) 1981-06-01 1982-12-08 Asahi Chem Ind Co Ltd Isoquinoline compound
JPS5993054A (ja) 1982-11-18 1984-05-29 Asahi Chem Ind Co Ltd イソキノリンスルホン酸アミド誘導体
JPS6081168A (ja) 1983-10-13 1985-05-09 Asahi Chem Ind Co Ltd アミジン誘導体
US4678783B1 (en) 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
JPS61227581A (ja) 1985-04-02 1986-10-09 Asahi Chem Ind Co Ltd 血管拡張剤
JPS61152658A (ja) 1984-12-27 1986-07-11 Asahi Chem Ind Co Ltd 置換されたイソキノリンスルホンアミド誘導体
EP0187371B1 (en) † 1984-12-27 1991-06-19 Asahi Kasei Kogyo Kabushiki Kaisha Substituted isoquinolinesulfonyl compounds
JPH0680054B2 (ja) * 1985-06-19 1994-10-12 吉富製薬株式会社 ピペリジン誘導体
JPH062741B2 (ja) 1985-10-29 1994-01-12 旭化成工業株式会社 ２級のイソキノリンスルホンアミド誘導体
JP2770497B2 (ja) * 1988-11-24 1998-07-02 吉富製薬株式会社 トランス―４―アミノ（アルキル）―１―ピリジルカルバモイルシクロヘキサン化合物およびその医薬用途
WO1990005723A1 (fr) † 1988-11-24 1990-05-31 Yoshitomi Pharmaceutical Industries, Ltd. Composes de trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane et leur utilisation en medecine
JP2720348B2 (ja) * 1989-03-30 1998-03-04 旭化成工業株式会社 脳細胞機能障害改善剤
JP3408546B2 (ja) * 1991-02-19 2003-05-19 旭化成株式会社 抗喘息剤
JP2864489B2 (ja) * 1991-02-27 1999-03-03 吉富製薬株式会社 喘息治療剤
DK0641781T3 (da) 1991-09-06 2000-09-18 Yoshitomi Pharmaceutical 4-Amino(alkyl)cyclohexan-1-carboxamidforbindelser og anvendelse af disse
JP3275389B2 (ja) * 1991-09-06 2002-04-15 三菱ウェルファーマ株式会社 ４−アミノ（アルキル）シクロヘキサン−１−カルボン酸アミド化合物
JPH05273821A (ja) 1992-03-24 1993-10-22 Nippon Steel Corp 静電画像形成装置
JP3265695B2 (ja) * 1992-05-12 2002-03-11 三菱ウェルファーマ株式会社 ４−置換アミノ（アルキル）シクロヘキサン−１−カルボン酸アミド化合物
JP2893029B2 (ja) 1992-08-10 1999-05-17 旭化成工業株式会社 心臓保護剤
JPH0680569A (ja) * 1992-09-03 1994-03-22 Asahi Chem Ind Co Ltd 血小板凝集阻害剤
JP3218356B2 (ja) 1993-03-31 2001-10-15 ヤンマー農機株式会社 管理機
JPH06289679A (ja) * 1993-04-01 1994-10-18 Hitachi Metals Ltd 画像形成方法
JP3464012B2 (ja) * 1993-04-05 2003-11-05 旭化成株式会社 精神症候治療剤
DE4323295C1 (de) * 1993-07-12 1995-02-09 Manfred R Dr Hamm Dosiervorrichtung
JPH0741424A (ja) * 1993-07-28 1995-02-10 Asahi Chem Ind Co Ltd 抗炎症剤
JPH07277979A (ja) * 1994-04-12 1995-10-24 Asahi Chem Ind Co Ltd 過粘性症候群治療または予防剤
EP1195372A1 (en) * 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
US5518911A (en) * 1995-01-06 1996-05-21 Onyx Pharmaceuticals, Inc. Human PAK65
NZ513800A (en) * 1996-08-12 2001-09-28 Welfide Corp Treatment of diseases using Rho kinase inhibitors

Also Published As

Publication number Publication date
NO990622L (no) 1999-04-12
DE69737631T2 (de) 2007-12-27
HUP9903694A3 (en) 2002-10-28
US20020032148A1 (en) 2002-03-14
CZ301044B6 (cs) 2009-10-21
US6218410B1 (en) 2001-04-17
DE69737631T3 (de) 2011-08-18
KR100576148B1 (ko) 2006-05-03
BG63991B1 (bg) 2003-09-30
HUP9903694A2 (hu) 2000-03-28
CA2263425A1 (en) 1998-02-19
BR9711154A (pt) 1999-08-17
ES2286834T3 (es) 2007-12-01
CN100389828C (zh) 2008-05-28
ATE359822T1 (de) 2007-05-15
US6906061B2 (en) 2005-06-14
EE9900050A (et) 1999-08-16
EP0956865A4 (en) 2001-05-16
SI0956865T1 (sl) 2007-10-31
WO1998006433A1 (en) 1998-02-19
AU738620B2 (en) 2001-09-20
KR20050055022A (ko) 2005-06-10
US6451825B1 (en) 2002-09-17
KR100595740B1 (ko) 2006-07-03
NO990622D0 (no) 1999-02-10
NZ513800A (en) 2001-09-28
SI0956865T2 (sl) 2011-04-29
BG103246A (en) 2000-05-31
IS4973A (is) 1999-02-11
RU2003103606A (ru) 2004-08-27
KR20000029918A (ko) 2000-05-25
DE69737631D1 (de) 2007-05-31
JP3669711B2 (ja) 2005-07-13
AU3785197A (en) 1998-03-06
EP0956865B1 (en) 2007-04-18
EP0956865B2 (en) 2010-08-18
IL128456A0 (en) 2000-01-31
HU229864B1 (en) 2014-10-28
PT956865E (pt) 2007-07-30
US20030134775A1 (en) 2003-07-17
RU2206321C2 (ru) 2003-06-20
RU2003104284A (ru) 2004-08-27
DK0956865T3 (da) 2007-09-03
ES2286834T5 (es) 2011-01-31
HK1022436A1 (en) 2000-08-11
EP0956865A1 (en) 1999-11-17
CZ46099A3 (cs) 1999-07-14
BG107645A (en) 2004-05-31
NZ334613A (en) 2002-02-01
PL331561A1 (en) 1999-07-19
BG107195A (en) 2003-05-30
CA2263425C (en) 2008-09-30
CN1233188A (zh) 1999-10-27
DK0956865T4 (da) 2010-11-22

Similar Documents

Publication Publication Date Title
BG63992B1 (bg) Амидно съединение и приложение му като rho киназен инхибитор
US5712270A (en) 2-arylamidothiazole derivatives with CNS activity
RU2125571C1 (ru) СОЛЬ 7-([1α,5α,6α]-6-АМИНО-3-АЗАБИЦИКЛО [3.1.0] ГЕКС-3-ИЛ)-6-ФТОР-1-(2,4-ДИФТОРФЕНИЛ)-1,4- ДИГИДРО-4-ОКСО-1,8-НАФТИРИДИН-3-КАРБОНОВОЙ И МЕТАНСУЛЬФОНОВОЙ КИСЛОТ И СПОСОБ ЕЕ ПОЛУЧЕНИЯ
JP2010505747A (ja) Ａ２ａアデノシンレセプタの選択的アンタゴニスト
US5342960A (en) Azomethines agonist compounds of the histamine H3 receptor for therapeutic use, pharmaceutical compositions acting as agonists of the said receptor and preparation process
CS262690B2 (en) Process for preparing 1-/hydroxystyryl/-5h-2,3-benzodiazepines
JPH02209876A (ja) イミダゾール誘導体
JPS62145049A (ja) アミノスチリル化合物及びそれを有効成分とするロイコトリエンきつ抗剤
EP0163537A1 (en) 1-Propanone derivatives and pharmaceutical compositions containing same
US5635511A (en) Treatment of heart rhythm disorders by administration of 3-phenylsulfonyl-3,7-diazabicyclo[3.3.1]nonane compounds.
US20090163541A1 (en) Quinuclidine compounds having quaternary ammonium group, its preparation method and use as blocking agents of acetylcholine
US4940789A (en) 10,11-dihydro-5-alkyl-12-substituted-10,5-(iminomethano)-5H-dibenzo[a,d]cycloheptenes as neuroprotectant agents
JPS63115865A (ja) デカヒドロキノリンの新誘導体、それらの製造法及びそれらを含む薬剤
US4851414A (en) Anti-dementia agent
KR20220050525A (ko) 항암, 항염증 효능을 가진 삼원환의 약학적 조성물
JPH0368574A (ja) 薬学的に活性なアミノイミダゾピリジン
JP2567593B2 (ja) イミダゾリジントリオン誘導体及び該化合物を有効成分として含有するアレルギ−性疾患治療剤
JPS6396187A (ja) インドローピラジノーベンゾジアゼピン誘導体
CS264293B2 (en) Process for preparing derivatives of 3-/hydroxymethyl/-isoquinoline
EP0346115A1 (en) Morpholine derivatives
JPS61218596A (ja) アルキルアミノ−フラノン誘導体
US4644004A (en) Pyridynecarboxylic esters of dopamine and of its N-alkyl derivatives
JPH0662608B2 (ja) カルボスチリル誘導体
JP2824381B2 (ja) Ｎ−（シクロアルキル）アルキルアゼピン誘導体およびその製造法
JPH04270222A (ja) 脳機能改善剤